ImaRx awarded four for ultrasound contrast patents:
This article was originally published in Clinica
Executive Summary
ImaRx Pharmaceutical has been issued four patents by the US Patent Office for its ultrasound contrast media. The patents cover a device for making specialised liposomes for therapeutic ultrasound applications; methods and apparatus for simultaneous diagnostic and therapeutic ultrasound; a drug-delivery system using liposomes for heart and lung therapy and a wide variety of perfluorocarbon-based liposomal contrast agents. ImaRx, based in Tucson, Arizona, is continuing research in thrombus targeting using ultrasound and has filed patents in this field.